Press releases
- Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing
- Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call
- Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology
- Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics
- Charles River to Perform Plasmid Production for Ship of Theseus
- Charles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024
- Charles River Laboratories Publishes 2023 Corporate Citizenship Report
- Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine
- Charles River and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration
- Charles River Laboratories to Present at Barclays Global Healthcare Conference
More ▼
Key statistics
On Friday, Charles River Laboratories International Inc (RV6:FRA) closed at 214.30, -14.89% below its 52-week high of 251.80, set on Mar 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 212.50 |
---|---|
High | 214.30 |
Low | 212.50 |
Bid | -- |
Offer | -- |
Previous close | 215.10 |
Average volume | 40.10 |
---|---|
Shares outstanding | 51.51m |
Free float | 50.58m |
P/E (TTM) | 24.66 |
Market cap | 11.72bn USD |
EPS (TTM) | 9.23 USD |
Data delayed at least 15 minutes, as of Apr 19 2024 15:33 BST.
More ▼